We're Here for You!
The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.
In this week’s blog, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie thoroughly discusses details on Tecvayli (teclistamab-cqyv)— a new bispecific antibody that was recently approved by the FDA for the treatment of relapsed or refractory multiple myeloma (RRMM). He delves into overall findings from the MajesTEC-1 Trial; in-hospital step-up dose schedule for teclistamab treatments; as well as follow-up treatment and supportive care. READ THE BLOG.
“Top Myeloma Research Presented at ASH 2022: What Patients and Care Partners Need to Know” will take place on Tuesday, December 20, 2022, at 4:00 p.m. PST | 5:00 p.m. MST | 6:00 p.m. CST | 7:00 p.m. EST. In this webinar, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G. M. Durie will summarize key takeaways from the 2022 American Society of Hematology (ASH) Annual Meeting that impact the myeloma community. Additionally, Dr. Durie will host a panel discussion highlighting the patient perspective with Linda Huguelet, IMF Support Group Leader of Chatanooga, TN; and Nick Lenoir, IMF Support Group Co-leader of Brooksville, FL. Both Linda and Nick are attending this year’s ASH annual meeting. REGISTER NOW.
Tune in as the IMF brings myeloma support group leaders and patients to the hybrid 64th annual meeting of the American Society of Hematology (ASH), an exciting convergence of 10,000 health care professionals from around the world. Start following the IMF ASH team members now on social media as they ramp up to share the latest clinical updates in myeloma research, therapies, and practice strategies via Twitter (#ASH22 and #IMFASH22), Facebook, blogs, and videos. Visit the ASH Blogs site now. VISIT NOW.
Physicians and other healthcare professionals who care for patients with multiple myeloma are eligible to earn CME/CE credits by attending the Friday IMF Satellite Symposium at ASH on December 9, 2022, at 11:00 a.m. CST at the Hyatt Regency New Orleans. This year’s symposium is “A Conversation with the Myeloma Experts: Making Sense of the Evolving Treatment Landscape,” and it precedes the 64th American Society of Hematology (ASH) Annual Meeting and Exposition. REGISTER NOW.
The International Myeloma Foundation (IMF) today announced it has been selected as a winner of the 2022 Amazon Web Services (AWS) IMAGINE Grant, a public grant opportunity open to registered 501(c) nonprofit organizations in the United States who are using technology to solve the world’s most pressing challenges. The grant will support the IMF’s efforts to use cloud technology to educate patients, unlock donor insights, increase fundraising, and more. LEARN MORE.
Recorded at the IMF’s 23rd Annual Support Group Leader's Summit, this episode of the "A Day in the Life" podcast features myeloma patient and support group leader Carl Burgman. Carl shares how he first discovered he had multiple myeloma, how he became a support group leader, and his passion for supporting newly diagnosed patients on their myeloma journeys. LISTEN NOW.
Need assistance in creating a fundraiser? The IMF team is here for you. Find out how you can help in the fight against myeloma today!